March 3, 2025
We’re excited to announce a strategic partnership between CETR China Europe Tech Regulatory and Medicilon Inc. (Medicilon USA Corp and Shanghai Medicilon Inc.) to support Medicilon’s business growth in Switzerland and across Europe.
With operations in the USA, China, and Europe, Medicilon is a leading CRO offering integrated pharmaceutical R&D services, including DMPK/PD, toxicology (GLP and non-GLP), chemistry, discovery biology, and CMC research. Since 2004, Medicilon has supported approximately 520 successful IND approvals worldwide, covering NCEs, biologics (e.g. mAbs, bispecific and trispecific antibodies), ADCs, RNA therapeutics, peptides, proteins, and vaccines. Their IND-enabling study packages support approvals from the US FDA, EMA, TGA, and NMPA.
In addition, Medicilon offers attractive large animal models (non-human primates, dogs, rabbits, and miniature pigs), tumor & non-tumor animal models (including Xenograft models, PDX / PDXO models), and support for simultaneous China-U.S. IND filing to streamline global drug development and approval.
Dr. Chunlin Chen, Founder, CEO, and Chairman of Medicilon, alongside Dr. Wei Hu, Founder and Managing Director of CETR, are enthusiastic about the immense potential within Europe’s biotech and pharma ecosystem - particularly Switzerland’s vibrant and innovative landscape.
Through this partnership, Medicilon aims to connect with more Swiss and European biotech and pharma companies, offering comprehensive support from drug discovery and development to preclinical animal studies and successful IND filings. CETR will serve as Medicilon’s local business representative in Switzerland, enhancing client support in this key market. Looking ahead, Medicilon also envisions establishing local research facilities in Switzerland.
We warmly welcome inquiries for potential projects and collaborations. Reach out to us at info@cetr.ch or +41 78 852 7130.
(See LinkedIn post original at https://www.linkedin.com/feed/update/urn:li:activity:7302328860438646784 )